{"id":11186,"date":"2021-07-21T00:00:00","date_gmt":"2021-07-21T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/conferences-2021-de-lasco-et-de-leha\/"},"modified":"2025-08-19T08:28:16","modified_gmt":"2025-08-19T13:28:16","slug":"conferences-2021-de-lasco-et-de-leha","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/07\/21\/conferences-2021-de-lasco-et-de-leha\/","title":{"rendered":"Conf\u00e9rences 2021 de l\u2019ASCO et de l\u2019EHA"},"content":{"rendered":"<p>Le Dr&nbsp;Joe Mikhael de l\u2019IMF a relev\u00e9 des th\u00e8mes de recherche int\u00e9ressants qui ont \u00e9merg\u00e9 des conf\u00e9rences virtuelles 2021 de l\u2019EHA (<em>European Hematology Association<\/em>) et de l\u2019ASCO (<em>American Society of Clinical Oncology<\/em>)&nbsp;:<\/p>\n<ol>\n<li>La th\u00e9rapie d\u2019induction<\/li>\n<li>L\u2019autogreffe de cellules souches<\/li>\n<li>Le r\u00f4le du traitement d\u2019entretien<\/li>\n<li>Le my\u00e9lome multiple \u00e0 haut risque, et<\/li>\n<li>Le my\u00e9lome r\u00e9cidivant-r\u00e9fractaire.<\/li>\n<\/ol>\n<p>Cliquez sur les liens ci-dessous pour en savoir plus&nbsp;:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=Q8i1seHGy0A\" target=\"_blank\" rel=\"noopener\"><em>International Myeloma Foundation<\/em> \u2013 Aper\u00e7u de l\u2019ASCO et de l\u2019EHA des principaux r\u00e9sum\u00e9s et affiches sur le my\u00e9lome multiple&nbsp;<\/a><\/li>\n<\/ul>\n<p>R\u00e9union annuelle 2021 de l\u2019ASCO<\/p>\n<ul>\n<li><a href=\"https:\/\/www.myeloma.org\/blog\/virtual-asco-2021-includes-important-new-data\" target=\"_blank\" rel=\"noopener\"><em>International Myeloma Foundation<\/em>&nbsp;<\/a><\/li>\n<li><a href=\"http:\/\/Nouvelles sur les meilleures pratiques\" target=\"_blank\" rel=\"noopener\">Nouvelles sur les meilleures pratiques<\/a><strong> <\/strong><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Le Dr&nbsp;Joe Mikhael de l\u2019IMF a relev\u00e9 des th\u00e8mes de recherche int\u00e9ressants qui ont \u00e9merg\u00e9 des conf\u00e9rences virtuelles 2021 de l\u2019EHA (European Hematology Association) et de l\u2019ASCO (American Society of Clinical Oncology)&nbsp;: La th\u00e9rapie d\u2019induction L\u2019autogreffe de cellules souches Le r\u00f4le du traitement d\u2019entretien Le my\u00e9lome multiple \u00e0 haut risque, et Le my\u00e9lome r\u00e9cidivant-r\u00e9fractaire. Cliquez [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11186","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11186"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11186\/revisions"}],"predecessor-version":[{"id":31296,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11186\/revisions\/31296"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}